scholarly journals IgG Subclasses and Antibodies to Group B Streptococci, Pneumococci, and Tetanus Toxoid in Preterm Neonates after Intravenous Infusion of Immunoglobulin to the Mothers

1986 ◽  
Vol 20 (10) ◽  
pp. 933-936 ◽  
Author(s):  
A Morell ◽  
D Sidiropoulos ◽  
U Herrmann ◽  
K K Christensen ◽  
P Christensen ◽  
...  
Keyword(s):  
Tetanus Toxoid ◽  
Intravenous Infusion ◽  
Igg Subclasses ◽  
Preterm Neonates ◽  
Group B Streptococci ◽  
Group B

IgG subclasses and antibodies to Group B streptococci in preterm neonates after intravenous infusion of immunoglobulin to the mothers

1986 ◽  
Vol 5 (3) ◽  
pp. S198 ◽  
Author(s):  
ANDREAS MORELL ◽  
DIMITRI SIDIROPOULOS ◽  
ULI HERRMANN ◽  
KAREN KVIST CHRISTENSEN ◽  
POUL CHRISTENSEN ◽  
...  
Keyword(s):  
Intravenous Infusion ◽  
Igg Subclasses ◽  
Preterm Neonates ◽  
Group B Streptococci ◽  
Group B

scholarly journals Pharmacokinetics of Penicillin G in Preterm and Term Neonates

2018 ◽  
Vol 62 (5) ◽  
Author(s):  
Helgi Padari ◽  
Tuuli Metsvaht ◽  
Eva Germovsek ◽  
Charlotte I. Barker ◽  
Karin Kipper ◽  
...  
Keyword(s):  
Compartment Model ◽  
Interquartile Range ◽  
Penicillin G ◽  
Preterm Neonates ◽  
Parameter Estimates ◽  
Group B Streptococci ◽  
Term Neonates ◽  
Extremely Preterm ◽  
Population Pk ◽  
Group B

ABSTRACTGroup B streptococci are common causative agents of early-onset neonatal sepsis (EOS). Pharmacokinetic (PK) data for penicillin G have been described for extremely preterm neonates but have been poorly described for late-preterm and term neonates. Thus, evidence-based dosing recommendations are lacking. We describe the PK of penicillin G in neonates with a gestational age (GA) of ≥32 weeks and a postnatal age of <72 h. Penicillin G was administered intravenously at a dose of 25,000 or 50,000 IU/kg of body weight every 12 h (q12h). At steady state, PK blood samples were collected prior to and at 5 min, 1 h, 3 h, 8 h, and 12 h after injection. Noncompartmental PK analysis was performed with WinNonlin software. With those data in combination with data from neonates with a GA of ≤28 weeks, we developed a population PK model using NONMEM software and performed probability of target attainment (PTA) simulations. In total, 16 neonates with a GA of ≥32 weeks were included in noncompartmental analysis. The median volume of distribution (V) was 0.50 liters/kg (interquartile range, 0.42 to 0.57 liters/kg), the median clearance (CL) was 0.21 liters/h (interquartile range, 0.16 to 0.29 liters/kg), and the median half-life was 3.6 h (interquartile range, 3.2 to 4.3 h). In the population PK analysis that included 35 neonates, a two-compartment model best described the data. The final parameter estimates were 10.3 liters/70 kg and 29.8 liters/70 kg forVof the central and peripheral compartments, respectively, and 13.2 liters/h/70 kg for CL. Considering the fraction of unbound penicillin G to be 40%, the PTA of an unbound drug concentration that exceeds the MIC for 40% of the dosing interval was >90% for MICs of ≤2 mg/liter with doses of 25,000 IU/kg q12h. In neonates, regardless of GA, the PK parameters of penicillin G were similar. The dose of 25,000 IU/kg q12h is suggested for treatment of group B streptococcal EOS diagnosed within the first 72 h of life. (This study was registered with the EU Clinical Trials Register under EudraCT number 2012-002836-97.)

scholarly journals Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates

1998 ◽  
Vol 78 (1) ◽  
pp. F46-F50 ◽  
Author(s):  
J. Kallman ◽  
J. Schollin ◽  
C. Schalen ◽  
A. Erlandsson ◽  
E. Kihlstrom
Keyword(s):  
Preterm Neonates ◽  
Group B Streptococci ◽  
Group B

scholarly journals Alpha C Protein as a Carrier for Type III Capsular Polysaccharide and as a Protective Protein in Group B Streptococcal Vaccines

1999 ◽  
Vol 67 (5) ◽  
pp. 2491-2496 ◽  
Author(s):  
Claudia Gravekamp ◽  
Dennis L. Kasper ◽  
Lawrence C. Paoletti ◽  
Lawrence C. Madoff
Keyword(s):  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Capsular Polysaccharide ◽  
Protein A ◽  
Surface Protein ◽  
Negative Control ◽  
Group B Streptococci ◽  
C Protein ◽  
Type Iii ◽  
Group B

ABSTRACT The alpha C protein, a protective surface protein of group B streptococci (GBS), is present in most non-type III GBS strains. Conjugate vaccines composed of the alpha C protein and type III capsular polysaccharide (CPS) might be protective against most GBS infections. In this study, the type III CPS was covalently coupled to full-length, nine-repeat alpha C protein (resulting in III-α9r conjugate vaccine) or to two-repeat alpha C protein (resulting in III-α2r conjugate vaccine) by reductive amination. Initial experiments with the III-α9r vaccine showed that it was poorly immunogenic in mice with respect to both vaccine antigens and was suboptimally efficacious in providing protection in mice against challenge with GBS. Therefore, modified vaccination protocols were used with the III-α2r vaccine. Female mice were immunized three times with 0.5, 5, or 20 μg of the III-α2r vaccine with an aluminum hydroxide adjuvant and bred. Ninety-five percent of neonatal mice born to dams immunized with the III-α2r vaccine survived challenge with GBS expressing type III CPS, and 60% survived challenge with GBS expressing wild-type (nine-repeat) alpha C protein; 18 and 17%, respectively, of mice in the negative control groups survived (P, <0.0001). These protection levels did not differ significantly from those obtained with the type III CPS-tetanus toxoid conjugate vaccine and the unconjugated two-repeat alpha C protein, which protected 98 and 58% of neonates from infection with GBS expressing type III CPS or the alpha C protein, respectively. Thus, the two-repeat alpha C protein in the vaccine was immunogenic and simultaneously enhanced the immunogenicity of type III CPS. III-α vaccines may be alternatives to GBS polysaccharide-tetanus toxoid vaccines, eliciting additional antibodies protective against GBS infection.

scholarly journals Immunization with C5a Peptidase or Peptidase-Type III Polysaccharide Conjugate Vaccines Enhances Clearance of Group B Streptococci from Lungs of Infected Mice

2002 ◽  
Vol 70 (11) ◽  
pp. 6409-6415 ◽  
Author(s):  
Qi Cheng ◽  
Steven Debol ◽  
Hong Lam ◽  
Ron Eby ◽  
Lorri Edwards ◽  
...  
Keyword(s):  
Tetanus Toxoid ◽  
Capsular Polysaccharide ◽  
Vaccine Development ◽  
Surface Protein ◽  
Histological Evaluation ◽  
Group B Streptococci ◽  
Type Iii ◽  
Rapid Clearance ◽  
Group B ◽  
The Impact

ABSTRACT Group B streptococci (GBS) are among the most common causes of life-threatening neonatal infections. Vaccine development since the late 1970s has focused on the capsular polysaccharides, but a safe, effective product is still not available. Our quest for a vaccine turned to the streptococcal C5a peptidase (SCPB). This surface protein is antigenically conserved across most if not all serotypes. A murine model was used to assess the impact of SCPB on clearance of GBS from the lungs of intranasally infected animals. Mutational inactivation of SCPB resulted in more-rapid clearance of streptococci from the lung. Immunization with recombinant SCPB alone or SCPB conjugated to type III capsular polysaccharide produced serotype-independent protection, which was evidenced by more-rapid clearance of the serotype VI strain from the lungs. Immunization of mice with tetanus toxoid-type III polysaccharide conjugate did not produce protection, confirming that protection induced by SCPB conjugates was independent of type III polysaccharide antigen. Histological evaluation of lungs from infected mice revealed that pathology in animals immunized with SCPB or SCPB conjugates was significantly less than that in animals immunized with a tetanus toxoid-polysaccharide conjugate. These experiments suggest that inclusion of C5a peptidase in a vaccine will both add another level to and broaden the spectrum of the protection of a polysaccharide vaccine.

Susceptibility to Six Antibiotics of Group B Streptococci Isolated from Cerebrospinal Fluid

1985 ◽  
Vol 17 (2) ◽  
pp. 191-193
Author(s):  
Chris Mulder ◽  
Pieter Bol ◽  
Arjan Nabbe ◽  
Bob Zanen
Keyword(s):  
Cerebrospinal Fluid ◽  
Group B Streptococci ◽  
Group B

scholarly journals Influence of group B streptococci on piglet pulmonary artery response to bradykinin

1999 ◽  
Vol 86 (1) ◽  
pp. 61-65 ◽  
Author(s):  
Richard M. Whitehurst ◽  
Rachel Laskey ◽  
Ronald N. Goldberg ◽  
Donald Herbert ◽  
Cornelius Van Breemen
Keyword(s):  
Pulmonary Artery ◽  
Contractile Response ◽  
Isometric Force ◽  
Control Group ◽  
Relaxed Controls ◽  
Vascular Response ◽  
Group B Streptococci ◽  
Resting Tension ◽  
Neonatal Group ◽  
Group B

To study whether a sepsis-induced increase in des-Arg9-bradykinin (des-Arg9-BK) and bradykinin (BK) B1-receptor activity participates in the observed increase in pulmonary vascular resistance in neonatal group B streptococcal sepsis (GBS), isometric force bioassays of pulmonary artery (PA) rings were studied, after 4-h exposure to either Krebs or GBS, by using the following protocols: 1) BK dose-response curve, 2) vascular response to BK with N G-nitro-l-arginine methyl ester (l-NAME), and 3) response to des-Arg9-BK (BK metabolite and B1 agonist). PA rings exposed to BK resulted in contraction in the GBS group and a decrease in resting tension in the Control group ( P = 0.034) at a concentration of 10−5 M. GBS-treated PA rings contracted more to des-Arg9-BK than did Controls ( P < 0.001). BK (10−6 M) relaxed preconstricted PA rings incubated in GBS less than BK relaxed Controls ( P < 0.001), and preincubation withl-NAME decreased relaxation in both. These results suggest that GBS decreased endothelium-dependent BK relaxation and increased contractile response to des-Arg9-BK. We speculate that this occurs secondary to upregulation of B1 receptors reflected by B1-agonist-mediated PA contraction.

Sign in / Sign up

Export Citation Format

Share Document